• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by RxSight Inc.

    2/25/25 4:54:13 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email
    S-8 1 2025_rxsight_s-8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 25, 2025
    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S‑8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    RXSIGHT, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    94-3268801

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

    100 Columbia

    Aliso Viejo, CA 92656

    (949) 521-7830

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

    2021 Equity Incentive Plan

    (Full title of the plan)

     

    Ron Kurtz, M.D.

    President and Chief Executive Officer

    RxSight, Inc.

    100 Columbia

    Aliso Viejo, CA 92656

    (949) 521-7830

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

     

     

     

    Martin J. Waters

    Robert L. Wernli, Jr.

    Wilson Sonsini Goodrich & Rosati, P.C.

    12235 El Camino Real

    San Diego, CA 92130

    (858) 350-2300

     

    Shelley Thunen

    Co-President and Chief Financial Officer

    RxSight, Inc.

    100 Columbia

    Aliso Viejo, CA 92656

    (949) 521-7830

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

     

    Smaller reporting company

    ☐

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐

     


    PART I


    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by RxSight, Inc. (the “Registrant”) for the purpose of registering 1,617,128 additional shares of common stock of the Registrant that may be issued pursuant to the RxSight, Inc. 2021 Equity Incentive Plan.

    In accordance with General Instruction E to Form S-8, the contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on July 30, 2021 (File No. 333-258292), Form S-8 filed by the Registrant with the SEC on March 8, 2022 (File No. 333-263374) and Form S-8 filed by the Registrant with the SEC on March 6, 2023 (File No. 333-270301) and Form S-8 filed by the Registrant with the SEC on February 28, 2024 (File No. 333-277487) are incorporated by reference into this Registration Statement.

     


    PART II

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

    (1)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 25, 2025 (the “Annual Report”);
    (2)
    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and
    (3)
    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-40690) filed with the SEC on July 28, 2021, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     


    Item 8. Exhibits.

     

    Exhibit

     

    Incorporated by Reference

    Number

    Description

    Form

    File No.

    Exhibit

    Filing Date

     

     

     

     

     

     

    4.1

    Specimen common stock certificate of the Registrant

     S-1/A

     333-257790

     4.2

     July 26, 2021

    4.2

    2021 Equity Incentive Plan, and form agreements thereunder

     10-K

      001-40690

     10.3

      February 25, 2025

    5.1*

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

    23.1*

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

    23.2*

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

     

     

     

     

    24.1*

    Power of Attorney (contained on signature page hereto)

     

     

     

     

    107*

    Filing Fee Table

     

     

     

     

    *

    Filed herewith.

     

     

     

     

     

     

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Aliso Viejo, State of California, on February 25, 2025.

     

    RXSIGHT, INC.

     

     

    By:

     

    /s/ Ron Kurtz, M.D.

     

     

    Ron Kurtz, M.D.

     

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Shelley Thunen as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in their name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Ron Kurtz, M.D.

     

    President, Chief Executive Officer and Director (Principal Executive Officer)

     

    February 25, 2025

    Ron Kurtz, M.D.

     

     

     

     

     

    /s/ Shelley Thunen

     

    Co-President and Chief Financial Officer

    (Principal Financial and Accounting Officer)

     

    February 25, 2025

    Shelley Thunen

     

     

     

     

     

    /s/ J. Andy Corley

     

    Chair of the Board

     

    February 25, 2025

    J. Andy Corley

     

     

     

     

     

    /s/ William J. Link, Ph.D.

     

    Director

     

    February 25, 2025

    William J. Link, Ph.D.

     

     

     

     

     

    /s/ Juliet Tammenoms Bakker

     

    Director

     

    February 25, 2025

    Juliet Tammenoms Bakker

     

     

     

     

     

    /s/ Julie Andrews

     

    Director

     

    February 25, 2025

    Julie Andrews

     

     

    /s/ Robert Palmisano

    Director

    February 25, 2025

    Robert Palmisano

    /s/ Robert Warner

     

    Director

     

    February 25, 2025

    Robert Warner

     

     

     

     

     

     

     

     

     

    /s/ Shweta Singh Maniar

    Director

    February 25, 2025

    Shweta Singh Maniar

     

     

     

     

     

    /s/ Tamara R. Fountain, M.D.

     

    Director

     

    February 25, 2025

    Tamara R. Fountain, M.D.

     

     

     

     

     


    Get the next $RXST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    1/30/2026Mkt Perform
    William Blair
    7/15/2025$9.00Overweight → Equal-Weight
    Morgan Stanley
    7/10/2025$9.00Buy → Hold
    Jefferies
    7/9/2025Outperform → Perform
    Oppenheimer
    7/9/2025$9.00Overweight → Equal Weight
    Wells Fargo
    7/9/2025Buy → Neutral
    BTIG Research
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    More analyst ratings

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition. Preliminary Unaudited Fourth Quarter and Full-year 2025 Results Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million, driven by: The sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®); representing a 10

    1/11/26 9:30:00 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

    ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. RxSight's management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surger

    1/2/26 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. Announces Chief Financial Officer Transition

    ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition. "Shelley has been a key and trusted partner throughout some of the most important years in RxSight's development," said Ron Kurtz, Chief Executive Officer and President of RxSight. "S

    12/22/25 5:15:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Wilterding Mark

    4 - RxSight, Inc. (0001111485) (Issuer)

    1/30/26 4:14:59 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Wilterding Mark

    3 - RxSight, Inc. (0001111485) (Issuer)

    1/30/26 4:14:02 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    New insider Gaines Scott claimed ownership of 11,167 shares (SEC Form 3)

    3 - RxSight, Inc. (0001111485) (Issuer)

    1/15/26 5:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    1/17/25 7:08:42 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    11/14/24 7:14:14 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    5/21/24 4:11:17 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    SEC Filings

    View All

    RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RxSight, Inc. (0001111485) (Filer)

    1/12/26 4:34:54 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RxSight, Inc. (0001111485) (Filer)

    12/23/25 5:21:44 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RxSight, Inc. (0001111485) (Filer)

    12/22/25 5:15:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on RxSight

    William Blair initiated coverage of RxSight with a rating of Mkt Perform

    1/30/26 7:00:55 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00

    7/15/25 8:39:07 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Jefferies with a new price target

    Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00

    7/10/25 8:36:38 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

    ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

    1/4/22 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/12/24 4:50:57 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/12/24 9:40:27 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Financials

    Live finance-specific insights

    View All

    RxSight, Inc. Reports Third Quarter 2025 Financial Results

    ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2025. Key Financial Highlights Reported third quarter 2025 revenue of $30.3 million, representing a decrease of 14% compared to the third quarter of 2024, reflecting: The sale of 26,045 Light Adjustable Lenses (LAL®/LAL+®), representing a 6% increase in procedure volume compared to the third quarter of 2024;The sale of 25 Light Delivery Devices (LDD™s), representing a 68% decrease compared to the third

    11/5/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

    ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company's investor relations

    10/22/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. Reports Second Quarter 2025 Financial Results

    ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the sec

    8/7/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care